Compare MTD & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTD | KVUE |
|---|---|---|
| Founded | 1991 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 33.1B |
| IPO Year | 1997 | 2023 |
| Metric | MTD | KVUE |
|---|---|---|
| Price | $1,403.81 | $17.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $1,423.33 | $20.00 |
| AVG Volume (30 Days) | 128.8K | ★ 32.7M |
| Earning Date | 02-05-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 4.81% |
| EPS Growth | 8.22 | ★ 35.31 |
| EPS | ★ 40.11 | 0.75 |
| Revenue | $3,941,791,000.00 | ★ $15,006,000,000.00 |
| Revenue This Year | $4.30 | N/A |
| Revenue Next Year | $4.73 | $2.81 |
| P/E Ratio | $34.76 | ★ $23.07 |
| Revenue Growth | ★ 4.77 | N/A |
| 52 Week Low | $946.69 | $14.02 |
| 52 Week High | $1,525.17 | $25.17 |
| Indicator | MTD | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 59.46 |
| Support Level | $1,399.68 | $16.93 |
| Resistance Level | $1,417.78 | $17.31 |
| Average True Range (ATR) | 22.07 | 0.21 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 49.20 | 71.82 |
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 28%, China about 16% and the rest of the world about 19%.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced November 2025 that it signed a deal to be fully acquired by Kimberly-Clark with the deal expected to close during the second half of 2026.